TapewireFind a company

organization · Reporting owner

Atlas Venture Associates XI, LLC

Disclosed activity across 8 companies

Tapewire entity
83425
SEC CIK
0001780067

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Akero Therapeutics, Inc.AKRO · Entity 7198410% ownerJune 24, 2019June 25, 2019
Day One Biopharmaceuticals, Inc.DAWN · Entity 5118010% ownerJune 17, 2022June 22, 2022
Dyne Therapeutics, Inc.DYN · Entity 394810% ownerFebruary 26, 2024February 28, 2024
ImageneBio, Inc.IKNA · Entity 713910% ownerMarch 30, 2021December 15, 2021
Korro Bio, Inc.KRRO · Entity 638810% ownerNovember 03, 2023November 07, 2023
Third Harmonic Bio, Inc.THRD · Entity 7651710% ownerSeptember 19, 2022September 19, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote3,469,759 Reported balance After 2019-06-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-06-24 · Conversion · Acquired 3,469,759 · Balance 3,469,759

F1: Represents the total number of shares of common stock received by Atlas Venture Fund XI, L.P. ("AVF XI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote235,099 Reported balance After 2019-06-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2019-06-24 · Conversion · Acquired 235,099 · Balance 235,099

F3: Represents the total number of shares of common stock received by Atlas Opportunity Fund I, L.P. ("AVO I") upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote505,099 Reported balance After 2019-06-24 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2019-06-24 · Purchase · Acquired 270,000 · Balance 505,099

F6: On June 24, 2019, AVO I purchased 270,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2019-06-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-06-24 · Conversion · Disposed 10,666,667 · Balance 0

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2019-06-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-06-24 · Conversion · Disposed 722,737 · Balance 0

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of common stock received by Atlas Venture Fund XI, L.P. ("AVF XI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F3: Represents the total number of shares of common stock received by Atlas Opportunity Fund I, L.P. ("AVO I") upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

F6: On June 24, 2019, AVO I purchased 270,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect766,667 Reported balance After 2022-06-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-06-17 · Purchase · Acquired 766,667 · Balance 766,667

F1: The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote7,210,242 Reported balance Holding disclosure · report date 2022-06-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 7,210,242

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote15,714 Reported balance Holding disclosure · report date 2022-06-17 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 15,714

F3: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote991,396 Reported balance Holding disclosure · report date 2022-06-17 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 991,396

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,698,091 Last balance in matching sequence After 2024-02-28 transaction · row 14 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2024-02-26 · Sale · Disposed 136,312 · Balance 6,216,250

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 2 · 2024-02-26 · Sale · Disposed 64,783 · Balance 6,151,467

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 7 · 2024-02-27 · Sale · Disposed 272,923 · Balance 5,878,544

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 8 · 2024-02-27 · Sale · Disposed 25,779 · Balance 5,852,765

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 13 · 2024-02-28 · Sale · Disposed 152,244 · Balance 5,700,521

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 14 · 2024-02-28 · Sale · Disposed 2,430 · Balance 5,698,091

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,564,932 Reported balance After 2024-02-26 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-02-26 · Sale · Disposed 20,205 · Balance 1,564,932

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,555,329 Reported balance After 2024-02-26 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2024-02-26 · Sale · Disposed 9,603 · Balance 1,555,329

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote909,107 Reported balance After 2024-02-26 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2024-02-26 · Sale · Disposed 11,736 · Balance 909,107

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote903,527 Reported balance After 2024-02-26 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2024-02-26 · Sale · Disposed 5,580 · Balance 903,527

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,514,874 Reported balance After 2024-02-27 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2024-02-27 · Sale · Disposed 40,455 · Balance 1,514,874

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,511,053 Reported balance After 2024-02-27 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2024-02-27 · Sale · Disposed 3,821 · Balance 1,511,053

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote880,022 Reported balance After 2024-02-27 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2024-02-27 · Sale · Disposed 23,505 · Balance 880,022

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote877,806 Reported balance After 2024-02-27 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 12 · 2024-02-27 · Sale · Disposed 2,216 · Balance 877,806

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,488,486 Reported balance After 2024-02-28 transaction · row 15 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 15 · 2024-02-28 · Sale · Disposed 22,567 · Balance 1,488,486

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,488,126 Reported balance After 2024-02-28 transaction · row 16 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 16 · 2024-02-28 · Sale · Disposed 360 · Balance 1,488,126

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote864,697 Reported balance After 2024-02-28 transaction · row 17 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 17 · 2024-02-28 · Sale · Disposed 13,109 · Balance 864,697

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote864,487 Reported balance After 2024-02-28 transaction · row 18 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 18 · 2024-02-28 · Sale · Disposed 210 · Balance 864,487

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote874,634 Reported balance After 2021-03-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-03-30 · Purchase · Acquired 125,000 · Balance 874,634

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect1,241,935 Last balance in matching sequence After 2021-12-14 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 2 · 2021-12-10 · Sale · Disposed 11,989 · Balance 1,256,224

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 3 · 2021-12-13 · Sale · Disposed 8,330 · Balance 1,247,894

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 4 · 2021-12-14 · Sale · Disposed 5,959 · Balance 1,241,935

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect177,217 Reported balance Holding disclosure · report date 2023-11-03 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 177,217

F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote942,075 Reported balance Holding disclosure · report date 2023-11-03 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 942,075

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,013,763 Reported balance After 2022-09-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-09-19 · Conversion · Acquired 6,472,374 · Balance 10,013,763

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect10,313,763 Reported balance After 2022-09-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-09-19 · Purchase · Acquired 300,000 · Balance 10,313,763

F3: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect594,096 Reported balance After 2022-09-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2022-09-19 · Conversion · Acquired 594,096 · Balance 594,096

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-09-19 · Conversion · Disposed 3,541,390 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-09-19 · Conversion · Disposed 2,282,537 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series A-3 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-09-19 · Conversion · Disposed 648,447 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2022-09-19 · Conversion · Disposed 594,096 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F5: The balance has been reduced by one share to adjust for an overstatemnet of one share in Reporting Person's Form 3 filed on September 14, 2022.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F3: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F5: The balance has been reduced by one share to adjust for an overstatemnet of one share in Reporting Person's Form 3 filed on September 14, 2022.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,886,293 Reported balance After 2025-02-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-02-10 · Conversion · Acquired 2,886,293 · Balance 2,886,293

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund II, L.P.807,727 Last balance in matching sequence After 2025-02-10 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2025-02-10 · Conversion · Acquired 747,727 · Balance 747,727

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Row 3 · 2025-02-10 · Purchase · Acquired 60,000 · Balance 807,727

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Series Seed convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-02-10 · Conversion · Disposed 1,051,051 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series A convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-02-10 · Conversion · Disposed 1,806,317 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series B convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-02-10 · Conversion · Disposed 1,298,332 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series C convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-02-10 · Conversion · Disposed 61,463 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series C convertible preferred stockSEC Table II · derivative / convertible securityIndirectBy Atlas Venture Opportunity Fund II, L.P.0 Reported balance After 2025-02-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-02-10 · Conversion · Disposed 1,092,504 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2024-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,019,563 Reported balance After 2024-02-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-02-08 · Sale · Disposed 733 · Balance 2,019,563

F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote734,546 Reported balance After 2024-02-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-02-08 · Sale · Disposed 267 · Balance 734,546

F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries C convertible preferred stock · Derivative 1,092,504 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 8

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 747,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries C convertible preferred stock · Derivative 61,463 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,068 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries B convertible preferred stock · Derivative 1,298,332 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 888,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries A convertible preferred stock · Derivative 1,806,317 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,236,271 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries Seed convertible preferred stock · Derivative 1,051,051 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 719,355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 PurchaseCommon Stock 60,000 $18.00 $1,080,000.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 807,727

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionCommon Stock 747,727 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 747,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionCommon Stock 2,886,293 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,886,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 210 $25.25 $5,302.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 18

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,487

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,109 $24.83 $325,496.47
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 17

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,697

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 360 $25.25 $9,090.00
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 16

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,126

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 22,567 $24.83 $560,338.61
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 15

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,486

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,430 $25.25 $61,357.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 14

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,698,091

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 152,244 $24.83 $3,780,218.52
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 13

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,700,521

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,216 $24.68 $54,690.88
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 12

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 877,806

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,505 $24.38 $573,051.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 11

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 880,022

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 3,821 $24.68 $94,302.28
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 10

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,511,053

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 40,455 $24.38 $986,292.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 9

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,514,874

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 25,779 $24.68 $636,225.72
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 8

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,852,765

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 272,923 $24.38 $6,653,862.74
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,878,544

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 5,580 $23.98 $133,808.40
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 903,527

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 11,736 $23.59 $276,852.24
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 909,107

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 9,603 $23.98 $230,279.94
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,555,329

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 20,205 $23.59 $476,635.95
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,564,932

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 64,783 $23.98 $1,553,496.34
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,151,467

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 136,312 $23.59 $3,215,600.08
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,216,250

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,738 $22.70 $311,852.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 920,843

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F10 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,648 $22.70 $536,809.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,585,137

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F8 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 159,542 $22.70 $3,621,603.40
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,352,562

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 22, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 119,360 $22.66 $2,704,697.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,512,104

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $23.1566 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 35,164 $23.14 $813,694.96
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,631,464

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7625 to $23.3899 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 149,337 $22.44 $3,351,122.28
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,666,628

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.72 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 20, 2024 Filed Feb 20, 2024 23:35 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 3,510 $23.40 $82,134.00
Disclosure

SEC source: 0001415889-24-004467 · form4-02202024_110225.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,815,965

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.01 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 20, 2024 Filed Feb 20, 2024 23:35 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 166,029 $22.71 $3,770,518.59
Disclosure

SEC source: 0001415889-24-004467 · form4-02202024_110225.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,819,475

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.117 to $23.09 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:35 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 162,707 $23.14 $3,765,039.98
Disclosure

SEC source: 0001415889-24-004467 · form4-02202024_110225.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,985,504

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.878 to $23.54 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:35 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,113 $24.45 $51,662.85
Disclosure

SEC source: 0001415889-24-004467 · form4-02202024_110225.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,148,211

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.51 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:35 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 175,793 $23.88 $4,197,936.84
Disclosure

SEC source: 0001415889-24-004467 · form4-02202024_110225.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,150,324

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.3943 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:33 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 267 $0.64 $170.88
Disclosure

SEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 734,546

F2 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:33 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 733 $0.64 $469.12
Disclosure

SEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,019,563

F1 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 12, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 560 $0.83 $464.80
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 734,813

F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 12, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 1,540 $0.83 $1,278.20
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,020,296

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 11, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 569 $0.87 $495.03
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 735,373

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9499 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 11, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 1,566 $0.87 $1,362.42
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,021,836

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9499 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:55 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 PurchaseCommon Stock 934,581 $10.70 $10,000,016.70
Disclosure

SEC source: 0001209191-22-061243 · doc4.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,581

F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 ConversionSeries B Preferred Stock · Derivative 594,096 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · derivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 594,096 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F5 · balance_after: The balance has been reduced by one share to adjust for an overstatemnet of one share in Reporting Person's Form 3 filed on September 14, 2022.

F4 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 ConversionSeries A-3 Preferred Stock · Derivative 648,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · derivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 648,447 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 ConversionSeries A-2 Preferred Stock · Derivative 2,282,537 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · derivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,282,537 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 ConversionSeries A-1 Preferred Stock · Derivative 3,541,390 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · derivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,541,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 ConversionCommon Stock 594,096 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 594,096

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F4 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
September 19, 2022 Filed Sep 19, 2022 16:51 UTC Third Harmonic Bio, Inc. THRD · Entity 76517 PurchaseCommon Stock 300,000 $17.00 $5,100,000.00
Disclosure

SEC source: 0001209191-22-050535 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,313,763

F3 · price: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.